Gencyte Therapeutics Inc.

San Carlos, CA

UEI
KLLTVAECBMN8
CAGE
7ZVP4
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Minority Owned Business
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
  • Asian-Pacific American Owned
Entity structure
Corporate Entity (Not Tax Exempt)
NAICS codes registered in SAM.gov
SAM.gov registration date
Physical address
560 Elm St #305, San Carlos, CA 94070, USA
Website
gencytetherapeutics.com
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

Gencyte Therapeutics Inc.'s 2 most recent federal contract and grant awards, newest first. Amounts are dollars obligated.
Award Agency Obligated Awarded
Phase i sbir concept award for logic gated molecular adaptor system for jmml treatment Contract · 75N91025C00046 National Cancer Institute $499,990
Gencyte therapeutics, INC. Proposes developing a synthetic notch receptor (synnotch) controlled precision molecular… Contract · 75N91023C00014 National Cancer Institute $354,964

Quick answers

What is Gencyte Therapeutics Inc.'s UEI?

Gencyte Therapeutics Inc.'s Unique Entity ID (UEI) in SAM.gov is KLLTVAECBMN8.

What is Gencyte Therapeutics Inc.'s CAGE code?

Gencyte Therapeutics Inc.'s CAGE code is 7ZVP4.

What is Gencyte Therapeutics Inc.'s primary NAICS code?

Gencyte Therapeutics Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Where is Gencyte Therapeutics Inc. located?

Gencyte Therapeutics Inc.'s physical address in SAM.gov is 560 Elm St #305, San Carlos, CA 94070, USA.

Is Gencyte Therapeutics Inc. registered in SAM.gov?

Yes. Gencyte Therapeutics Inc.'s SAM.gov registration is active through March 5, 2027.

What is Gencyte Therapeutics Inc.'s most recent federal award?

Gencyte Therapeutics Inc.'s most recent federal contract award is Phase i sbir concept award for logic gated molecular adaptor system for jmml treatment (75N91025C00046), from National Cancer Institute, on September 12, 2025.

On GovTribe

See Gencyte Therapeutics Inc.'s full federal record

  • Federal contract awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login